ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,553.82
0.89%
US Tech 100
19,295.20
1.50%
Dow Jones
40,433.80
0.36%
Brent Oil
81.525
-0.92%
Bitcoin
66,691.40
-2.15%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) News

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:TEVA
DateTimeSourceHeadlineSymbolCompany
07/18/20248:30AMBusiness WireTeva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic MigraineNYSE:TEVATeva Pharmaceutical Industries Ltd
07/02/20246:00PMBusiness WireTeva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
06/28/20246:34PMBusiness WireLes nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiquesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/28/20243:41PMBusiness WireNeue Daten zu AJOVY® (Fremanezumab) zur Migräneprävention stellen Behandlungspausen in FrageNYSE:TEVATeva Pharmaceutical Industries Ltd
06/28/202411:30AMBusiness WireNew AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment PausesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/25/20248:00AMBusiness WireTeva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020NYSE:TEVATeva Pharmaceutical Industries Ltd
06/24/20249:50AMBusiness WireTeva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20248:03AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20248:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:41AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:38AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:27AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:23AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:20AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:17AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/17/20247:14AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/14/20247:21AMIH Market NewsAdobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and MoreNYSE:TEVATeva Pharmaceutical Industries Ltd
06/04/20244:05PMBusiness WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/20242:25PMBusiness WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)NYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/20242:20PMBusiness WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
05/29/20246:38PMBusiness WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)NYSE:TEVATeva Pharmaceutical Industries Ltd
05/20/20248:25PMBusiness WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
05/20/20248:25PMGlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
05/15/20248:36AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/15/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
05/15/20248:15AMBusiness WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsNYSE:TEVATeva Pharmaceutical Industries Ltd
05/09/20247:53AMIH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:TEVATeva Pharmaceutical Industries Ltd
05/08/20247:00AMBusiness WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
05/08/20246:30AMBusiness WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
05/02/20246:30PMBusiness WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Your Recent History

USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
INCT
Incapta (PK)
USOTC
HIRU
Hiru (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
RONN
Ronn Motor (PK)
USOTC
NBRI
North Bay Resources (PK)
USOTC
CNNA
Cann American (CE)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
COOP
Mr Cooper
USOTC
AABB
Asia Broadband (PK)
USOTC
BLEG
Branded Legacy (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
FNMA
Fannie Mae (QB)
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved